Noyce, A; (2020) The impact of COVID-19 on access to Parkinson’s disease medication. Movement Disorders , 35 (12) pp. 2129-2133. 10.1002/mds.28293.

Preview

Text Noyce_mds.28293.pdf - Published Version Download (360kB) | Preview

Abstract

Background: Many countries have implemented drastic measures to fight the COVID‐19 pandemic. Restrictions and diversion of resources may have negatively affected patients with Parkinson's disease (PD). Our aim was to examine whether COVID‐19 had an impact on access to PD medication by region and income. Methods: This study was conducted as part of a survey sent to members of the Movement Disorders Society focusing on access to PD medication globally. Results: Of 346 responses, 157 (45.4%) agreed that COVID‐19 had affected access to PD medication, while 189 (54.6%) disagreed. 22.8% of high‐income and 88.9% of low‐income countries' respondents agreed that access to PD medication was affected by COVID‐19. 59% of all ‘yes' respondents reported increased disability of patients as an impact. Conclusions: Access to PD medication is likely to have been affected by COVID‐19 and result in deterioration of patients' symptomatic control. Resource‐poor countries appear to be disproportionately affected compared to more affluent countries. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Download activity - last month

Export as CSVXMLJSON

Download activity - last 12 months

Export as JSONCSVXML

Downloads by country - last 12 months

Export as JSONXMLCSV

Archive Staff Only

View Item